LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Начало・Списък с акции・Heron Therapeutics Inc

Heron Therapeutics Inc

Затворен

СекторЗдравеопазване

0.86 -2.27

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.85

Максимум

0.87

Ключови измерители
By Trading Economics
Приходи	-5.2M -8.1M
Продажби	-5.9M 35M
EPS	-0.04
Марж на печалбата	-23.367
Служители	128
EBITDA	-4M -4.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+302.3% upside

Дивиденти
By Dow Jones
Следващи печалби	7.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-68M 163M
Предишно отваряне	3.13
Предишно затваряне	0.86

Настроения в новините

By Acuity

12%

88%

14 / 344 Класиране в Healthcare

Heron Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.05.2026 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29.05.2026 г., 20:53 ч. UTC

Печалби

Oil Declines Lift Stocks to Fresh Records -- WSJ

29.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 20:33 ч. UTC

Пазарно говорене

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29.05.2026 г., 20:11 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 19:47 ч. UTC

Печалби

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29.05.2026 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29.05.2026 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29.05.2026 г., 18:19 ч. UTC

Пазарно говорене

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29.05.2026 г., 18:12 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29.05.2026 г., 18:11 ч. UTC

Пазарно говорене

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29.05.2026 г., 18:10 ч. UTC

Пазарно говорене

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29.05.2026 г., 17:55 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 17:55 ч. UTC

Пазарно говорене

NEAR Protocol Nearly Doubles in May -- Market Talk

29.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29.05.2026 г., 17:00 ч. UTC

Печалби

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

29.05.2026 г., 16:02 ч. UTC

Пазарно говорене

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29.05.2026 г., 15:40 ч. UTC

Пазарно говорене

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Canada's Economy Not Looking All That Bright -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Heron Therapeutics Inc Прогноза

Ценова цел

By TipRanks

302.3% нагоре

12-месечна прогноза

Среден 3.5 USD 302.3%

Висок 4 USD

Нисък 3 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Heron Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Heron Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

14 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.